VolitionRx Schedules Third Quarter 2015 Earnings Conference Call and Business Update for Wednesday, November 4, 2015 at 8:30am ET
VolitionRx Demonstrates NuQ® Blood Test Detects 95% of Pancreatic Cancers in Second Preliminary Study
VolitionRx Announces Publication of Results from Pancreatic Cancer Study with Lund University in Clinical Epigenetics
VolitionRx Announces First CE Mark for NuQ(R) Blood Assay for Detection of Colorectal Cancer
VolitionRx Granted Its First U.S. Patent
VolitionRx Demonstrates NuQ(R) Blood Test Detects 81% of Colorectal Cancers and 67% of High Risk Adenomas in Large Double Blinded Clinical Trial
VolitionRx to Present at Rodman & Renshaw 17th Annual Global Investment Conference in New York and CNAPS IX Conference in Berlin on September 9 and 11, 2015
VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015
VolitionRx Announces Appointment of David Kratochvil as Chief Financial Officer
VolitionRx Announces Second Quarter 2015 Financial Results and Business Update
